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Abstract 
Background: Food allergy is an important public health problem because it affects children and adults, can be 
severe and even life‑threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of 
Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the 
first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other 
emerging data suggest that peanut allergy can be prevented through introduction of peanut‑containing foods 
beginning in infancy.
Objectives: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient 
advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum 
guidelines to specifically address the prevention of peanut allergy.
Results: The addendum provides 3 separate guidelines for infants at various risk levels for the development of 
peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the defini‑
tion of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food chal‑
lenges), and the timing and approaches for introduction of peanut‑containing foods in the health care provider’s 
office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each 
recommendation.
Conclusions: Guidelines have been developed for early introduction of peanut‑containing foods into the diets of 
infants at various risk levels for peanut allergy.
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Background
Peanut allergy is a growing public health problem. In 
1999, peanut allergy was estimated to affect 0.4% of chil-
dren and 0.7% of adults in the United States [1], and by 
2010, peanut allergy prevalence had increased to approxi-
mately 2% among children in a national survey [2], with 
similar results reported in a regional cohort [3]. Peanut 
allergy is the leading cause of death related to food-
induced anaphylaxis in the United States [4, 5], and 
although overall mortality is low, the fear of life-threat-
ening anaphylactic reactions contributes significantly to 
the medical and psychosocial burden of disease. In the 
majority of patients, peanut allergy begins early in life 
and persists as a lifelong problem. Therefore, cost-effec-
tive measures to prevent peanut allergy would have a 
high effect in terms of improving public health, reducing 
personal suffering, and decreasing health care use and 
costs.
The “Guidelines for the diagnosis and management of 
food allergy in the United States” [6] were published in 
December 2010 by an expert panel and a Coordinating 
Committee convened by the National Institute of Allergy 
and Infectious Diseases (NIAID). These guidelines did 
not offer strategies for the prevention of food allergy and 
particularly peanut allergy because of a lack of definitive 
studies at the time. The guidelines indicated that “insuf-
ficient evidence exists for delaying introduction of solid 
foods, including potentially allergenic foods, beyond 
4–6 months of age, even in infants at risk of developing 
allergic disease.” This statement differed from previous 
clinical practice guidelines in the United Kingdom [7] 
and United States, [8] which recommended the exclusion 
of allergenic foods from the diets of infants at high risk 
for allergy and is consistent with more recent recommen-
dations regarding primary allergy prevention [9–12].
In February 2015, the New England Journal of Medi-
cine published the results of the Learning Early about 
Peanut Allergy (LEAP) trial [13]. This trial was based on 
a prior observation [14] that the prevalence of peanut 
allergy was tenfold higher among Jewish children in the 
United Kingdom compared with Israeli children of simi-
lar ancestry. In Israel, peanut-containing foods are usually 
introduced in the diet when infants are approximately 
7  months of age and consumed in substantial amounts, 
whereas in the United Kingdom children do not typi-
cally consume any peanut-containing foods during their 
first year of life. The LEAP trial randomized 640 children 
between 4 and 11 months of age with severe eczema, egg 
allergy, or both to consume or avoid peanut-containing 
foods until 60 months of age, at which time a peanut oral 
food challenge (OFC) was conducted to determine the 
prevalence of peanut allergy. LEAP trial participants were 
stratified at study entry into 2 separate study cohorts 
on the basis of pre-existing sensitization to peanut, as 
determined by means of skin prick testing: one cohort 
consisted of infants with no measureable skin test wheal 
to peanut (negative skin test response) and the other 
consisted of those with measurable wheal responses 
(1–4 mm in diameter). Infants with a 5 mm wheal diam-
eter or greater were not randomized because the majority 
of infants at this level of sensitization were presumed to 
be allergic to peanut. Among the 530 participants in the 
intention-to-treat population with negative baseline skin 
test response to peanut, the prevalence of peanut allergy 
at 60  months of age was 13.7% in the peanut avoid-
ance group and 1.9% in the peanut consumption group 
(P < .001; an 86.1% relative reduction in the prevalence of 
peanut allergy). Among the 98 participants with a meas-
urable peanut skin test response at entry, the prevalence 
of peanut allergy was 35.3% in the avoidance group and 
10.6% in the consumption group (P = .004; a 70% relative 
reduction in the prevalence of peanut allergy).
The LEAP trial was the first randomized trial to study 
early allergen introduction as a preventive strategy. 
Because of the size of the observed effect and the large 
number of study participants, its outcome received wide 
publicity in both the medical community and the press. 
This raised the need to operationalize the LEAP find-
ings by developing clinical recommendations focusing 
on peanut allergy prevention. To achieve this goal and its 
wide implementation, the NIAID invited the members of 
the 2010 Guidelines Coordinating Committee and other 
stakeholder organizations to develop this addendum on 
peanut allergy prevention to the 2010 “Guidelines for the 
diagnosis and management of food allergy in the United 
States.” Twenty-six stakeholder organizations partici-
pated in this 2015–2016 Coordinating Committee. Of 
note, unrelated to this effort, a consensus statement on 
behalf of 9 international professional societies regarding 
the implications and implementation of the LEAP trial 
findings was published as well [15].
Additional evidence on early introduction of aller-
genic foods comes from the LEAP-On study [16], which 
demonstrated the durability of oral tolerance to peanut 
achieved in the LEAP trial and the enquiring about tol-
erance study [17], which assessed the potential benefits 
of early introduction of 6 allergenic foods in a non–high-
risk cohort.
Development of the 2017 addendum to the 2010 
“Guidelines for the diagnosis and management 
of food allergy”
The process to develop the 2017 addendum closely fol-
lowed that used in the 2010 guidelines [6].
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Coordinating committee
The NIAID established a Coordinating Committee (CC), 
the members of which are listed in Appendix A, to over-
see the development of the addendum; review drafts of 
the addendum for accuracy, practicality, clarity, and broad 
utility of the recommendations in clinical practice; review 
and approve the final addendum; and disseminate the 
addendum. The CC members represented 26 professional 
organizations, advocacy groups, and federal agencies.
Expert panel
The CC convened an expert panel (EP) in June 2015 that 
was chaired by Joshua Boyce, MD. The 26 panel mem-
bers, listed in Appendix B, were specialists from a vari-
ety of relevant clinical, scientific, and public health areas. 
Panel members were nominated by the CC organizations, 
and the composition of the panel received unanimous 
approval by the CC member organizations.
The charge to the EP was to use the literature review 
prepared by the NIAID (see the next section) in conjunc-
tion with consensus expert opinion and EP-identified 
supplementary documents to (1) develop evidence-based 
recommendations for the early introduction of dietary 
peanut to prevent peanut allergy; (2) agree on principles 
for grading the evidence; (3) achieve consensus while 
allowing ample opportunity for consideration of diver-
gent opinions; (4) determine whether the recommenda-
tions could extend beyond peanut to other food allergens; 
and (5) keep patient and societal interests at the fore-
front. The new recommendations are intended to supple-
ment and modify guidelines 37 to 40 in Section 5.3.4 of 
the 2010 guidelines: “Prevention of food allergy.”
Literature review
NIAID staff conducted a literature search of PubMed 
limited to the years 2010 (January) to 2016 (June). Using 
the following specific search terms ([food allergy or milk 
allergy or egg allergy or peanut allergy] OR [eczema or 
atopic dermatitis] AND prevention), PubMed returned 
more than 1500 articles. NIAID staff reviewed 1506 
abstracts and assessed each for relevance to the topic 
of food allergy prevention with an emphasis on peanut 
allergy. Sixty-four publications (original research articles, 
editorials/letters, and systematic reviews) were deemed 
relevant and placed into 2 tiers: tier 1 contained 18 items 
considered highly relevant to the early introduction of 
peanut or other allergenic foods (see Appendix C), and 
tier 2 contained 46 items on related topics, such as food 
allergy or eczema prevention.
Assessing the quality of the body of evidence
For each of the 18 tier 1 references, the EP assessed 
quality by using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach [18]. GRADE provides a comprehensive and 
transparent methodology to develop recommenda-
tions for the diagnosis, treatment, and management of 
patients. In assessing the body of evidence of a group of 
relevant articles or of a single article, GRADE consid-
ers study design and other factors, such as the precision, 
consistency, and directness of the data. By using this 
approach, GRADE then provides a categorical assess-
ment of the contribution of individual publications and 
the overall quality and strength of the body of evidence.
Each publication was assigned a grade according to the 
following criteria [19, 20]:
  • High: further research is very unlikely to have an 
effect on the quality of the body of evidence, and 
therefore the confidence in the recommendation is 
high and unlikely to change.
  • Moderate: further research is likely to have an effect 
on the quality of the body of evidence and may 
change the recommendation.
  • Low: further research is very likely to have an impor-
tant effect on the body of evidence and is likely to 
change the recommendation.
A GRADE designation of “low” for the quality of evi-
dence does not imply that an article is not factually 
correct or lacks scientific merit. For example, a well-
designed and executed single-site study of a treatment in 
a small cohort of highly selected subjects may still yield 
an overall GRADE rating of “low.” This is because such a 
study is characterized as providing “sparse” data, and the 
patient population may not be representative of the at-
risk population. Each of these factors reduces the level of 
evidence from “high,” which is the initial designation for 
evidence from randomized controlled trials. It is worth 
emphasizing that these 2 limitations are not of the study 
per se but of the body of evidence.
Preparation of the draft addendum
The draft version of the addendum, prepared by the 
NIAID, contained 3 new guidelines and was reviewed, 
modified, and endorsed by the EP members. The EP-
approved document was forwarded to the CC members 
for review.
Public comment period, addendum revision, and final 
approval
Concurrent with CC member review, the draft adden-
dum was posted to the NIAID Web site in March 2016 
for a period of 45  days to allow for public review and 
comment. One hundred four comments were received. 
All comments were reviewed by the EP and the CC, and 
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some contributed to the final revision of the addendum. 
The final addendum was reviewed and approved by the 
EP and the CC.
Dissemination of the addendum guidelines
The final addendum is published herein and available 
through the Internet.
Defining the strength of each clinical guideline
The EP has used the verb “recommends” or “suggests” for 
each clinical recommendation.
These words convey the strength of the recommenda-
tion, defined as follows:
  • Recommend is used when the EP strongly recom-
mended for or against a particular course of action.
  • Suggest is used when the EP weakly recommended 
for or against a particular course of action.
Addendum guidelines
Table  1 provides a summary of the 3 addendum guide-
lines to be used as a quick reference.
The EP came to consensus on the following 3 defini-
tions used throughout the addendum guidelines.
  • Severe eczema is defined as persistent or frequently 
recurring eczema with typical morphology and dis-
tribution assessed as severe by a health care pro-
vider and requiring frequent need for prescrip-
tion-strength topical corticosteroids, calcineurin 
inhibitors, or other anti-inflammatory agents despite 
appropriate use of emollients.
  • Egg allergy is defined as a history of an allergic reac-
tion to egg and a skin prick test (SPT) wheal diameter 
of 3 mm or greater with egg white extract, or a posi-
tive oral egg food challenge result.
  • A specialist is defined as a health care provider with 
the training and experience to (1) perform and inter-
pret SPTs and OFCs and (2) know and manage their 
risks. Such persons must have appropriate medica-
tions and equipment on site.
Addendum guideline 1
The EP recommends that infants with severe eczema, egg 
allergy, or both have introduction of age-appropriate pea-
nut-containing food as early as 4–6 months of age to reduce 
the risk of peanut allergy. Other solid foods should be intro-
duced before  peanut-containing foods to show that the 
infant is developmentally ready. The EP recommends that 
evaluation with peanut-specific IgE (peanut sIgE) measure-
ment, SPTs, or both be strongly considered before introduc-
tion of peanut to determine if peanut should be introduced 
and, if so, the preferred method of introduction. To mini-
mize a delay in peanut introduction for children who may 
test negative, testing for peanut sIgE may be the preferred 
initial approach in certain health care settings, such as fam-
ily medicine, paediatrics, or dermatology practices, in which 
skin prick testing is not routine. Alternatively, referral for 
assessment by a specialist may be an option if desired by the 
health care provider and when available in a timely manner.
Figure 1 provides recommended approaches for evalu-
ation of children with severe eczema, egg allergy, or both 
before peanut introduction.
A peanut sIgE level of less than 0.35 kUA/L has strong 
negative predictive value for the diagnosis of peanut 
allergy [21]. Therefore, peanut sIgE testing may help in 
certain health care settings (eg,  family medicine, paedi-
atric, or dermatology practices, where skin prick testing 
is not routine) to reduce unnecessary referrals of children 
with severe eczema, egg allergy, or both and to minimize 
a delay in peanut introduction for children who may have 
negative test results. However, the EP emphasizes that 
a peanut sIgE level of 0.35 kUA/L or greater lacks ade-
quate positive predictive value for the diagnosis of pea-
nut allergy, and an infant with a value of 0.35 kUA/L or 
greater should be referred to a specialist.
Thus, peanut sIgE testing can place an infant into one 
of 2 categories (Fig. 1):
  • sIgE Category A: If the peanut sIgE level is less than 
0.35 kUA/L (ImmunoCAP), the EP recommends that 
peanut should be introduced in the diet soon thereaf-
ter, with a cumulative first dose of approximately 2 g 
Table 1 Summary of addendum guidelines 1, 2, and 3
Addendum 
guideline
Infant criteria Recommendations Earliest age of peanut introduction
1 Severe eczema, egg 
allergy, or both
Strongly consider evaluation by sIgE measurement 
and/or SPT and, if necessary, an OFC. Based on test 




Introduce peanut‑containing foods Around 6 months
3 No eczema or any  
food allergy
Introduce peanut‑containing foods Age appropriate and in accordance with family 
preferences and cultural practices
Page 5 of 20Togias et al. Allergy Asthma Clin Immunol  (2017) 13:1 
of peanut protein given in this feeding. This can be 
given as a feeding at home (Appendix D), consider-
ing the low likelihood of a severe allergic reaction. If 
the caregiver or health care provider has concerns, a 
supervised feeding can be offered at the health care 
provider’s office (Appendix E).
  • sIgE Category B: If the peanut sIgE level is 0.35 
kUA/L or greater (ImmunoCAP), the EP recom-
mends that the child be referred to a specialist for 
further consultation and possible skin prick testing.
The EP does not recommend food allergen panel test-
ing or the addition of sIgE testing for foods other than 
peanut because of their poor positive predictive value, 
which could lead to misinterpretation, overdiagnosis of 
food allergy, and unnecessary dietary restrictions [6].
SPTs with peanut extract can place an infant in one of 3 
categories (Fig. 1):
  • SPT Category A: If an SPT to peanut extract pro-
duces a wheal diameter of 2 mm or less above saline 
control, the EP recommends that peanut be intro-
duced in the diet soon after testing, with a cumula-
tive first dose of approximately 2  g of peanut pro-
tein given in this feeding. This can be given at home 
(Appendix D), considering the low likelihood of 
a severe allergic reaction. If the caregiver or health 
care provider has concerns, a supervised feeding can 
be offered at the health care provider’s office (Appen-
dix E).
  • SPT Category B: If an SPT to peanut extract pro-
duces a wheal diameter of 3 to 7  mm greater than 
Fig. 1 Recommended approaches for evaluation of children with severe eczema and/or egg allergy before peanut introduction
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that elicited by the saline control, the EP suggests 
that a supervised peanut feeding or a graded OFC 
be undertaken at a specialist’s office or a special-
ized facility (see Appendices E and G, respectively). 
Infants in this category can be sensitized without 
being allergic to peanut and might benefit from early 
peanut consumption. If the supervised peanut feed-
ing or graded OFC yields no reaction, the EP recom-
mends that peanut should be added to the child’s 
diet. If the supervised peanut feeding or the graded 
OFC results in an allergic reaction, the EP recom-
mends that the child should strictly avoid dietary 
peanut and the family should be counselled regarding 
food allergy management.
  • SPT Category C: If an SPT produces a wheal diam-
eter 8 mm or greater than that elicited by the saline 
control, the likelihood of peanut allergy is high. Chil-
dren in this category should continue to be evaluated 
and managed by a specialist [21–23].
Box 1 Important considerations for skin prick testing
SPT reagents, testing devices, and methodology can differ significantly 
among health care providers in the United States or elsewhere.22 The 
EP recommends that specialists adjust their SPT categorization criteria 
according to their own training and experience.
Health care providers conducting OFCs in infants with 3 mm or greater 
SPT responses should be aware that the probability of a positive chal‑
lenge response increases with wheal size. These data come from the 
HealthNuts Study in children 12 to 18 months of age; of note, the sever‑
ity of these reactions was relatively mild [21, 23].
How much dietary peanut protein to introduce
If the decision is made to introduce dietary peanut based 
on the recommendations of addendum guideline 1, the 
total amount of peanut protein to be regularly consumed 
per week should be approximately 6 to 7 g over 3 or more 
feedings (see Appendix F). In the LEAP trial, at evalua-
tions conducted at 12 and 30 months of age, 75% of chil-
dren in the peanut consumption group reported eating at 
least this amount of peanut, based on analysis of a 3-day 
food diary recorded just before the evaluation.
Rationale
Infants with severe eczema, egg allergy, or both are at 
high risk for the development of peanut allergy. Signifi-
cant evidence on this group is available from the infants 
who participated in the LEAP trial or were screened for 
the LEAP trial but were not enrolled because of a large 
SPT response (>4  mm). At 60  months of age, approxi-
mately 23% of peanut avoiders and those infants not 
enrolled had food allergy [24].
Balance of benefits and harms
In the LEAP trial, among the 530 participants in the 
intention-to-treat population with negative baseline SPT 
responses to peanut, 13.7% of the avoidance group and 
1.9% of the consumption group had peanut allergy at 
60 months of age (P < .001; a 12.6% absolute risk reduc-
tion and an 86.1% relative risk reduction in the preva-
lence of peanut allergy, resulting in a number needed 
to treat of 8.5 [number of infants needed to have early 
introduction of peanut to prevent peanut allergy in one 
child]). Among the 98 participants with positive peanut 
SPT responses at entry, 35.3% of the avoidance group and 
10.6% of the consumption group had peanut allergy at 
60 months of age (P = .004; a 24.7% absolute risk reduc-
tion and a 70% relative risk reduction in the prevalence 
of peanut allergy, resulting in a number needed to treat 
of 4).
The LEAP-on study [24] demonstrated that the ben-
efits achieved in the LEAP trial persisted when LEAP 
trial peanut consumers subsequently avoided peanut for 
1  year from 60 to 72  months of age. This indicates that 
the oral tolerance achieved in the LEAP trial was durable.
The LEAP trial did not include infants with SPT wheals 
greater than 4 mm, and therefore no data are available on 
the potential effectiveness of peanut consumption in pre-
venting peanut allergy in this group. However, EP mem-
bers believe it is possible that some of these infants may 
benefit from early introduction of peanut provided that 
they tolerate oral peanut.
As shown in Fig.  1, the EP recommends that infants 
with severe eczema, egg allergy, or both, with peanut sIgE 
levels of less than 0.35 kUA/L or with a peanut SPT wheal 
of 2 mm or less have dietary peanut introduced as early 
as 4–6 months of age without a need for further evalua-
tion. This recommendation is supported by expert opin-
ion and analysis of the LEAP population findings. In the 
LEAP trial, infants consuming peanut in this post hoc 
defined category had a relative risk reduction of 79% of 
having peanut allergy at 60 months of age compared with 
infants who avoided peanut.
In the LEAP trial, at study entry, all infants randomly 
assigned to the consuming group had a baseline peanut 
OFC. Of the 272 infants with no wheal induced by peanut 
SPT and who received a baseline oral peanut challenge, 
only 1 had a reaction presenting as an erythematous urti-
carial rash that was graded as a “moderate” adverse event 
and was treated successfully with chlorpheniramine. 
Among the 29 infants with a wheal diameter of 1–2 mm 
who received a baseline oral peanut challenge, 2 had 
reactions, which also presented with mild symptoms not 
requiring treatment with epinephrine. Therefore, for the 
SPT Category A children, the risk of a severe reaction to 
peanut at first introduction is low, and introduction of 
peanut at home is an option. However, it is understand-
able that some caregivers of infants with severe eczema, 
egg allergy, or both may be uncomfortable introducing 
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dietary peanut at home. In such cases the health care 
provider should offer the option of a supervised feeding 
of a peanut-containing food in the office.
The rate of positive peanut OFC results at baseline for 
infants with a 3–4 mm wheal diameter (4/17 infants) 
was higher than in infants with 0 to 2 mm wheal diam-
eters (3/301 infants), but the elicited symptoms were 
mild. Infants with larger wheal diameters (>4 mm) were 
not included in the LEAP trial, and therefore no safety 
data are available from this group. However, based on 
the Australian HealthNuts study, which conducted pea-
nut OFCs in a large number of older (12–18  months 
old) children from the general Australian population, 
the rate of reactions to peanut is expected to be substan-
tially higher with increasing SPT wheal diameter [21, 23]. 
In the HealthNuts study [23] an SPT wheal diameter of 
8 mm or greater had a 95% positive predictive value for 
peanut allergy (positive oral peanut challenge result). 
Therefore, the EP recommends that for SPT Category 
B infants (3–7  mm SPT wheal diameter), a supervised 
feeding or a graded peanut OFC should be conducted 
in a specialist’s office or a specialized facility (Appendix 
G). SPT Category C infants are considered high risk for 
established allergy to peanut and should not receive pea-
nut-containing foods in their diet, unless such foods are 
recommended by a specialist after further evaluation.
Quality of evidence: moderate
The designation of the quality of evidence as “moder-
ate” (as opposed to “high”) is based on the fact that this 
recommendation derives primarily from a single rand-
omized, open-label study: the LEAP trial. However, it 
should be noted that the assessment of the LEAP trial’s 
primary outcome was based on a double-blind, pla-
cebo-controlled OFC. Furthermore, confidence in this 
recommendation is bolstered by the large effect size dem-
onstrated in the LEAP trial and prior epidemiologic data 
that peanut allergy is relatively infrequent in Israel, where 




1. Breast-feeding recommendations: the EP recognizes 
that early introduction of peanut may seem to depart 
from recommendations for exclusive breast-feeding 
through 6 months of age [25, 26]. However, it should 
be noted that data from the nutrition analysis of the 
LEAP cohort [27] indicate that introduction of pea-
nut did not affect the duration or frequency of breast-
feeding and did not influence growth or nutrition.
2. Age of peanut introduction: for children with severe 
eczema, egg allergy, or both, the EP recommends that 
introduction of solid foods begins at 4–6 months of 
age, starting with solid food other than peanut, so 
that the child can demonstrate the ability to consume 
solid food without evidence of nonspecific signs and 
symptoms that could be confused with IgE-mediated 
food allergy. However, it is important to note that 
infants in the LEAP trial were enrolled between 4 
and 11  months of age and benefitted from peanut 
consumption regardless of age at entry. Therefore, if 
the 4- to 6-month time window is missed for any rea-
son, including developmental delay, infants may still 
benefit from early peanut introduction. On the other 
hand, older age at screening is associated with larger 
wheal diameters induced by peanut SPT and hence a 
higher likelihood of established peanut allergy [28].
 A practical consideration for applying this guideline 
at 4–6 months of age is that infants visit their health 
care provider for well-child evaluations and infant 
immunizations at this time. This provides a fortui-
tous opportunity for eczema evaluation, caregiver 
reporting of egg allergy, and, if needed, referral to a 
specialist for peanut allergy evaluation before dietary 
introduction of peanut.
3. Considerations for family members with established 
peanut allergy: the EP recognizes that many infants 
eligible for early peanut introduction under this 
guideline will have older siblings or caregivers with 
established peanut allergy. The EP recommends that 
in this situation caregivers discuss with their health 
care providers the overall benefit (reduced risk of 
peanut allergy in the infant) versus risk (potential for 
further sensitization and accidental exposure of the 
family member to peanut) of adding peanut to the 
infant’s diet.
4. Children identified as allergic to peanut: for children 
who have been identified as allergic to peanut, the 
EP recommends strict peanut avoidance. This may 
include those children in SPT Category B who fail 
the supervised peanut feeding or the OFC, or those 
children in SPT Category C who, on further evalu-
ation by a specialist, are confirmed as being allergic 
to peanut. These children should be under long-term 
management by a specialist.
Addendum guideline 2
The EP suggests that infants with mild-to-moderate 
eczema should have introduction of age-appropri-
ate peanut-containing food around 6  months of age, 
in accordance with family preferences and cultural 
practices, to reduce the risk of peanut allergy. Other 
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solid foods should be introduced before peanut-
containing foods to show that the infant is develop-
mentally ready. The EP recommends that infants in 
this category may have dietary peanut introduced at 
home without an in-office evaluation. However, the 
EP recognizes that some caregivers and health care 
providers may desire an in-office supervised feeding, 
evaluation, or both.
Rationale
The LEAP trial did not target infants with mild or moder-
ate eczema. The EP considered the potential risk/benefit 
ratio of early dietary peanut introduction in infants with 
mild-to-moderate eczema and concluded that the indi-
vidual and societal benefits of introducing peanut in this 
population would be significant. The EP has no reason to 
believe that the mechanisms of protection of early dietary 
peanut differ in infants with mild-to-moderate eczema 
from those that lead to protection in infants at higher risk 
of peanut allergy.
Balance of benefits and harms
The LEAP trial included only infants with severe eczema 
or egg allergy based on careful medical history. There-
fore, some infants who participated in the LEAP trial 
based on the presence of egg allergy had atopic derma-
titis severity scores (SCORAD scores [29]) at screening 
that would have placed them in the moderate or mild 
eczema category. The EP considered the outcomes of 
these children and concluded that infants with mild-to-




The quality of evidence is low because this recommen-





Additional support for early introduction of peanut in 
infants who do not have severe eczema comes from the 
Enquiring About Tolerance study [17], which enrolled 
infants from the general population at 3 months of age 
and sequentially introduced 6 allergenic foods begin-
ning at the time of enrolment. These children were not 
intentionally selected based on increased risk of food 
allergy or atopy. Although the intention-to-treat group 
did not show benefit, most likely because of relatively 
poor compliance with feeding recommendations, the 
children in the per-protocol group who had peanut 
introduced early in infancy showed a significant reduc-
tion in peanut sensitization and peanut allergy at age 
3  years. This study also provides support for guideline 
3 below.
Addendum guideline 3
The EP suggests that infants without eczema or any food 
allergy have age-appropriate peanut-containing foods 
freely introduced in the diet together with other solid 
foods and in accordance with family preferences and cul-
tural practices.
Rationale
No evidence exists for restricting allergenic foods in 
infants without known risks for food allergy. The proba-
bility for development of peanut allergy in such children 
is very low. However, approximately 14% of all children 
with peanut allergy at age 12–18 months in the Health-
Nuts Study lacked known risk factors for food allergy 
[16]. Consequently, because such children constitute a 
significant majority of any birth cohort, they contribute 
substantially to the overall societal burden of peanut 
allergy. The EP finds no evidence to suggest that mecha-
nisms of oral tolerance induction would differ in these 
infants from the immunologic mechanisms that are pro-
tective in infants at higher risk of peanut allergy. Thus, 
the early introduction of dietary peanut in children 
without risk factors for peanut allergy is generally antici-
pated to be safe and to contribute modestly to an overall 
reduction in the prevalence of peanut allergy. Further-
more, in countries such as Israel, where peanut products 
are a popular component of the diet and where they are 
introduced early in life, the prevalence of peanut allergy 
is low [14].
Balance of benefits and harms
The EP acknowledges that any analysis of benefit and 
harm in this population relies primarily on expert opin-
ion and is subject to current differences in regional/
societal rates of peanut consumption and peanut sen-
sitization. In countries where peanut products are not 
widely consumed by adults, early dietary introduction 
of peanut could lead to an increase in sensitization and 
allergic manifestations. Hence the EP cautions that this 
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Box 2 Clinical implications
These guidelines will help health care providers with early introduction 
of peanut‑containing foods in infants at various risk levels for peanut 
allergy. Early introduction of peanut will result in the prevention of 
peanut allergy in a large number of infants.
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Appendix D. Instructions for home feeding 
of peanut protein for infants at low risk of an 
allergic reaction to peanut
These instructions for home feeding of peanut protein 
are provided by your doctor. You should discuss any 
questions that you have with your doctor before start-
ing. These instructions are meant for feeding infants who 
have severe eczema or egg allergy and were allergy tested 
(blood test, skin test, or both) with results that your doc-
tor considers safe for you to introduce peanut protein at 
home (low risk of allergy).
General instructions
1. Feed your infant only when he or she is healthy; do 
not do the feeding if he or she has a cold, vomiting, 
diarrhea, or other illness.
2. Give the first peanut feeding at home and not at a day 
care facility or restaurant.
3. Make sure at least 1 adult will be able to focus all of 
his or her attention on the infant, without distrac-
tions from other children or household activities.
4. Make sure that you will be able to spend at least 2 h 
with your infant after the feeding to watch for any 
signs of an allergic reaction.
Feeding your infant
1. Prepare a full portion of one of the peanut-containing 
foods from the recipe options below.
2. Offer your infant a small part of the peanut serving 
on the tip of a spoon.
3. Wait 10 min.
4. If there is no allergic reaction after this small taste, 
then slowly give the remainder of the peanut-con-
taining food at the infant’s usual eating speed.
What are symptoms of an allergic reaction? What should I 
look for?
  • Mild symptoms can include:
 – a new rash
or
 – a few hives around the mouth or face
  • More severe symptoms can include any of the follow-
ing alone or in combination:
 – lip swelling
  – vomiting
  – widespread hives (welts) over the body
  – face or tongue swelling
  – any difficulty breathing
  – wheeze
  – repetitive coughing
  – change in skin color (pale, blue)
 – sudden tiredness/lethargy/seeming limp
If you have any concerns about your infant’s response 
to peanut, seek immediate medical attention/call 911.
Four recipe options, each containing approximately 2 g 
of peanut protein
Note: Teaspoons and tablespoons are US measures (5 and 
15 mL for a level teaspoon or tablespoon, respectively).
Option 1: Bamba (Osem, Israel), 21 pieces (approxi-
mately 2 g of peanut protein)
Note: Bamba is named because it was the product used 
in the LEAP trial and therefore has proven efficacy and 
safety. Other peanut puff products with similar peanut 
protein content can be substituted.
Page 14 of 20Togias et al. Allergy Asthma Clin Immunol  (2017) 13:1 
a. For infants less than 7  months of age, soften the 
Bamba with 4 to 6 teaspoons of water.
b. For older infants who can manage dissolvable tex-
tures, unmodified Bamba can be fed. If dissolvable 
textures are not yet part of the infant’s diet, softened 
Bamba should be provided.
Option 2: Thinned smooth peanut butter, 2 teaspoons 
(9–10 g of peanut butter; approximately 2 g of peanut 
protein)
a. Measure 2 teaspoons of peanut butter and slowly add 
2 to 3 teaspoons of hot water.
b. Stir until peanut butter is dissolved, thinned, and well 
blended.
c. Let cool.
d. Increase water amount if necessary (or add previ-
ously tolerated infant cereal) to achieve consistency 
comfortable for the infant.
Option 3: Smooth peanut butter puree, 2 teaspoons 
(9–10  g of peanut butter; approximately 2  g of peanut 
protein)
a. Measure 2 teaspoons of peanut butter.
b. Add 2 to 3 tablespoons of previously tolerated pureed 
fruit or vegetables to peanut butter. You can increase 
or reduce volume of puree to achieve desired consist-
ency.
Option 4: Peanut flour and peanut butter powder, 2 tea-
spoons (4 g of peanut flour or 4 g of peanut butter pow-
der; approximately 2 g of peanut protein)
Note: Peanut flour and peanut butter powder are 2 dis-
tinct products that can be interchanged because they 
have, on average, a similar peanut protein content.
a. Measure 2 teaspoons of peanut flour or peanut but-
ter powder.
b. Add approximately 2 tablespoons (6–7 teaspoons) of 
pureed tolerated fruit or vegetables to flour or pow-
der. You can increase or reduce the volume of puree 
to achieve desired consistency.
Appendix E. For health care providers: In‑office 
supervised feeding protocol using 2 g of peanut 
protein
General instructions
1. These recommendations are reserved for an infant 
defined in guideline 1 as one with severe eczema, egg 
allergy, or both and with negative or minimally reac-
tive (1 to 2 mm) SPT responses and/or peanut sIgE 
levels of less than 0.35 kUA/L. They also may apply 
to the infant with a 3 to 7 mm SPT response if the 
specialist health care provider decides to conduct 
a supervised feeding in the office (as opposed to a 
graded OFC in a specialized facility [see Fig. 1]).
 These recommendations can also be followed for 
infants with mild-to-moderate eczema, as defined in 
guideline 2, when caregivers and health care provid-
ers may desire an in-office supervised feeding.
2. Proceed only if the infant shows no evidence of any 
concomitant illness, such as an upper respiratory 
tract infection.
a. Start with a small portion of the initial peanut 
serving, such as the tip of a teaspoon of peanut 
butter puree/softened Bamba.
b. Wait 10  minutes; if there is no sign of reac-
tion after this small portion is given, continue 
gradually feeding the remaining serving of pea-
nut-containing food (see options below) at the 
infant’s typical feeding pace.
c. Observe the infant for 30  minutes after 2  g of 
peanut protein ingestion for signs/symptoms of 
an allergic reaction.
Four recipe options, each containing approximately 2 g 
of peanut protein
Note: Teaspoons and tablespoons are US meas-
ures (5 and 15  mL for a level teaspoon or tablespoon, 
respectively).
Option 1: Bamba (Osem, Israel), 21 pieces (approxi-
mately 2 g of peanut protein)
Note: Bamba is named because it was the product used 
in the LEAP trial and therefore has known peanut pro-
tein content and proven efficacy and safety. Other peanut 
puffs products with similar peanut protein content can 
be substituted for Bamba.
a. For infants less than 7  months of age, soften the 
Bamba with 4 to 6 teaspoons of water.
b. For older infants who can manage dissolvable tex-
tures, unmodified Bamba can be fed. If dissolvable 
textures are not yet part of the infant’s diet, softened 
Bamba should be provided.
Option 2: Thinned smooth peanut butter, 2 teaspoons 
(9–10 g of peanut butter; approximately 2 g of peanut 
protein)
a. Measure 2 teaspoons of peanut butter and slowly add 
2 to 3 teaspoons hot water.
b. Stir until peanut butter is dissolved and thinned and 
well blended.
c. Let cool.
Page 15 of 20Togias et al. Allergy Asthma Clin Immunol  (2017) 13:1 
d. Increase water amount if necessary (or add previ-
ously tolerated infant cereal) to achieve consistency 
comfortable for the infant.
Option 3: Smooth peanut butter puree, 2 teaspoons 
(9–10 g of peanut butter; approximately 2 g of peanut 
protein)
a. Measure 2 teaspoons of peanut butter.
b. Add 2 to 3 tablespoons of previously tolerated pureed 
fruit or vegetables to peanut butter. You can increase 
or reduce volume of puree to achieve desired consist-
ency.
Option 4: Peanut flour and peanut butter powder, 2 tea-
spoons (4 g of peanut flour or 4 g of peanut butter pow-
der; approximately 2 g of peanut protein)
Note: Peanut flour and peanut butter powder are 2 dis-
tinct products that can be interchanged because they 
have, on average, a similar peanut protein content.
a. Measure 2 teaspoons of peanut flour or peanut but-
ter powder.
b. Add approximately 2 tablespoons (6–7 teaspoons) of 
pureed tolerated fruit or vegetables to flour or pow-
der. You can increase or reduce the volume of puree 
to achieve desired consistency.
Appendix F. Peanut protein in peanut‑containing 
foods
If the decision is made to introduce dietary peanut to 
the infant’s diet, the total amount of peanut protein to be 
regularly consumed per week should be approximately 6 
to 7 g over 3 or more feedings. In the LEAP trial, at evalu-
ations conducted at 12 and 24 months of age, 75% of chil-
dren in the peanut consumption group reported eating at 
least this amount of peanut.
Be aware of choking risks
  • Whole nuts should not be given to children less than 
5 years of age.
  • Peanut butter directly from a spoon or in lumps/dol-
lops should not be given to children less than 4 years 
of age.
If, after a week or more eating peanut, your infant or 
child displays mild allergic symptoms within 2 h of eating 
peanut, you should contact your health care provider.
Typical peanut-containing foods, their peanut pro-
tein content, and feeding tips for infants are provided 
in Table  2, and their nutritional content is found in 
Table 3.
Appendix G. Graded OFC protocol
From “Conducting an oral food challenge to peanut in an 
infant: a work group report” [30].
General instructions
1. A graded OFC should be performed only by a spe-
cialist with the training and experience to (1) per-
form and interpret skin prick testing and OFCs and 
(2) know and manage their risks. Such persons must 
have appropriate medications and equipment on site. 
2. Four peanut preparations are provided:
a. Option 1: Smooth peanut butter mixed with 
either a previously tolerated pureed fruit or veg-
etable.
b. Option 2: Smooth peanut butter dissolved care-
fully with hot water and cooled.
c. Option 3: Peanut flour mixed with either a previ-
ously tolerated pureed fruit or vegetable. Peanut 
butter powder can be used instead of the peanut 
flour.
d. Option 4: Bamba peanut snack dissolved in 
hot water and cooled or even as a solid (ie, as a 
stick).
 Note: Bamba (Osem, Israel) is named because 
it was the product used in the LEAP trial and 
therefore has known peanut protein content and 
proven efficacy and safety. Other peanut puff 
products with similar peanut protein content 
can be substituted for Bamba.
3. The peanut protein content of the graded OFC pro-
tocol is identical for all peanut preparations provided 
below, except that the volume of food ingested per 
dose is different. The  protocol consists of 5 incre-
mental doses, given 15 to 20 min apart, with a cumu-
lative peanut protein total  of approximately 4  g per 
the 3.9 g total in the LEAP trial.
4. Refer to Table  4 and direct parents to discontinue 
specific medications for the prescribed amount of 
time before the graded OFC. Note that certain medi-
cations are allowed.
Be prepared in case of a severe reaction (see Table 5)
Note: Teaspoons and tablespoons are US measures (5 and 
15 mL for a level teaspoon or tablespoon, respectively).
Protocol instructions for options 1, 2, and 3 (see Tables 6, 
7, and 8)
1. Measure peanut butter, peanut flour, or peanut butter 
powder for dose 1.
2. Prepare the first dose:
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a. If using option 1, add previously tolerated 
pureed fruit or vegetable to measured dose 1 
peanut butter and stir  until well blended. You 
can increase or reduce volume of puree to 
achieve desired consistency. Note: Increasing 
the volume may increase the difficulty of getting 
through the entire protocol with a young baby.
b. If using option 2, slowly add hot water to meas-
ured dose 1 peanut butter and stir until peanut 
butter is dissolved, thinned, and well blended. 
Let the mixture cool. You can increase water vol-
ume (or add previously tolerated infant cereal) 
to achieve desired consistency.
c. If using option 3, add previously tolerated 
pureed fruit or vegetable to measured dose 1 
peanut flour or peanut butter powder and stir 
until well blended. You can increase or reduce 
volume of puree to achieve desired consistency. 
Note: Increasing the volume may increase the 
difficulty of getting through entire protocol with 
a young baby.
3. Label dose 1.
4. Repeat steps 1 to 3 for the remaining doses 2 through 
5, labeling each dose appropriately and before pro-
ceeding to the preparation of the next dose.
Table 3 Nutritional content of peanut‑containing foods
a The nutritional content of peanut puff products (other than Bamba) can be obtained from their manufacturers
Per approximately 2 g of peanut 
protein
Bambaa (17 g) Peanut butter (10 g) Peanuts (8 g) Peanut butter powder (4 g) Peanut flour (4 g)
kcal 93 59 45 15 13
Sugar (g) 0.4 0.65 0.38 0.4 0.33
Salt (mg) 68 48 1 31 7
Fat (g) 6.1 4.95 3.94 0.49 0.02
Table 4 Medication discontinuation considerations 
before OFC






Short‑acting bronchodilator (eg, albuterol) 8 h
Medications that can be continued
 Antihistamine eye drops
 Inhaled/intranasal corticosteroids
 Topical (cutaneous) steroids
 Topical (cutaneous) pimecrolimus, tacrolimus
Table 5 Emergency medications for a severe reaction during an office‑based infant OFC
IM, intramuscular; MDI, metered-dose inhaler
Medication Dose
First‑line treatment Epinephrine (1:1000 concentration) 0.01 mg/kg IM in the mid‑outer thigh in health care settings
or
0.15 mg of autoinjector IM in the mid‑outer thigh in community settings
Epinephrine doses may need to be repeated every 5‑15 min
Adjunctive treat‑
ment
Albuterol nebulization 0.15 mg/kg every 20 min × 3 doses (minimum of 2.5 mg per dose) over 
5‑15 min
Albuterol MDI inhalation 2 puffs, 90 μg per puff, with face mask
Oxygen 8‑10 L/min through a face mask
Diphenhydramine 1.25 mg/kg administered orally
Cetirizine 2.5 mg administered orally
Normal saline (0.9% isotonic solution) or lactated 
ringers
20 ml/kg per dose administered over 5 min intravenously
Steroids Prednisolone 1 mg/kg administered orally
or
Solu‑Medrol 1 mg/kg administered intravenously
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Table 6 Option 1: Measures for smooth peanut butter puree
a Amounts (volume) of peanut butter measured as teaspoons are approximate measures to keep the dosing as practical as possible
b Peanut protein content is calculated on the average amount of protein for a range of butters using “Report: 16167, USDA Commodity, Peanut Butter, smooth,” from 
the USDA Nutrition Database (http://ndb.nal.usda.gov/ndb/foods)
c Three teaspoons = 1 tablespoon
Dose Peanut butter volumea Equivalent weight of peanut butter (g 
[peanut protein content in grams])b
Pureed fruit or vegetable volume Total volume
1 1/8 teaspoon 0.67 (0.15) 1/2 teaspoon 5/8 teaspoon
2 1/4 teaspoon 1.33 (0.29) 3/4 teaspoon 1 teaspoons
3 1/2 teaspoon 2.67 (0.59) 1 teaspoons 1 1/2 teaspoons
4 1 teaspoon 5.33 (1.17) 2 teaspoons 3 teaspoonsc
5 1 1/2 teaspoons 8 (1.6) 4 teaspoons 5 1/2 teaspoons
Total protein: 3.96 g
Table 7 Option 2: Measures for smooth thinned peanut butter
a Amounts (volume) of peanut butter measured as teaspoons are approximate measures to keep the dosing as practical as possible
b Peanut protein content is calculated on the average amount of protein for a range of butters using “Report: 16167, USDA Commodity, Peanut Butter, smooth,” from 
the USDA Nutrition Database (http://ndb.nal.usda.gov/ndb/foods)
c Three teaspoons = 1 tablespoon
Dose Peanut butter 
volumea
Equivalent weight peanut butter (g 
[peanut protein content in grams])b
Volume of hot water Total volume
1 1/8 teaspoon 0.67 (0.15) 1/8 teaspoon 1/4 teaspoon
2 1/4 teaspoon 1.33 (0.29) 1/4 teaspoon 1/2 teaspoon
3 1/2 teaspoon 2.67 (0.59) 1/2 teaspoon 1 teaspoon
4 1 teaspoon 5.33 (1.17) 1 teaspoon 2 teaspoons
5 1 1/2 teaspoons 8 (1.76) 1 1/2 teaspoons 3 teaspoonsc
Total protein: 3.96 g
Table 8 Option 3: Measures for peanut flour or peanut butter powder
a Amounts (volume) of peanut flour or peanut butter powder measured as teaspoons are approximate measures to keep the dosing as practical as possible
b Information regarding peanut powder and flour reflects averages obtained from the producers. Most brands of peanut flour/peanut butter powder are 
approximately 50% peanut protein by weight. However, weight can vary based on the fat content and also the brand chosen. Therefore a weight measurement can be 
more accurate than household measurements
c Three teaspoons = 1 tablespoon
d Six teaspoons = 2 tablespoons
Dose Peanut flour or peanut 
butter powder volumea
Equivalent weight peanut flour or 
peanut butter powderb (g [peanut 
protein content in grams])
Pureed fruit or vegetable volume Total volume
1 1/8 teaspoon 0.25 (0.13) 1/2 teaspoon 3/4 teaspoon
2 1/4 teaspoon 0.5 (0.25) 1 teaspoon 1 1/4 tea‑
spoons
3 1/2 teaspoon 1.0 (0.5) 2 teaspoons 2 1/2 tea‑
spoons
4 1 teaspoon 2.0 (1.0) 3 teaspoonsc 4 teaspoons
5 2 teaspoons 4.0 (2.0) 6 teaspoonsd 8 teaspoons
Total protein: 3.88 g
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5. Feed dose 1 to infant and observe for symptoms of 
reactivity for 15 to 20 min.
6. If no symptoms appear, repeat with dose 2 and 
observe for 15 to 20 min.
7. Continue in this manner with doses 3, 4, and 5.
  Protocol instructions for option 4 (see Table 9)
1. Count Bamba sticks for dose 1.
2. Prepare the first dose by slowly adding hot water to 
measured Bamba and stirring until Bamba is dis-
solved, thinned, well blended, and cooled. You can 
increase water volume to achieve desired consist-
ency. Note: Increasing the volume may increase the 
difficulty of getting through the entire protocol with a 
young baby.
3. Label dose 1.
4. Repeat steps 1 to 3 for the remaining doses 2 through 
5, labeling each dose appropriately and before pro-
ceeding to the preparation of the next dose.
5. Feed dose 1 to the infant and observe for symptoms 
of reactivity for 15 to 20 min.
6. If no symptoms appear, repeat with dose 2 and 
observe for 15 to 20 min.
7. Continue in this manner with doses 3, 4, and 5.
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